In a recent press release, Windtree Therapeutics, Inc.(NasdaqCM: WINT) announced a significant development in its efforts to advance interventions for critical cardiovascular disorders.The biotechnology company revealed that it has entered into an Exchange and Termination Agreement with affiliates of Deerfield Management Company, effectively eliminating a $15 million contingent liability associated with AEROSURF.This agreement marks a pivotal moment for Windtree in its pursuit of treating premature infants with respiratory distress syndrome, as it frees up resources and consolidates its financial position.
AEROSURF and the Out-Licensing of Global Rights:AEROSURF is an acute pulmonary drug/device combination designed to address respiratory distress syndrome in premature infants.Under the terms of the 2017 Exchange and Termination Agreement, Deerfield was en
Comments